The future looks bright for Replimune Group Inc (REPL) Stock

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

What is Replimune Group Inc’s (REPL) Stock Real Technical Picture?

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Earnings and valuation of Replimune Group Inc (REPL) Stock are impressive

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Invest in Replimune Group Inc (REPL) Stock with the prospect of future returns

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Growing at an Unbelievable Rate: Replimune Group Inc (REPL) Stock

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]